The following is a summary of “Acceptant And Commitment Therapy To Increase Compliance To Sexual Dysfunction Treatments In Men With Prostate Cancer: 6- And 12-Month Data From A Randomized Controlled Trial,” published in the April 2023 issue of Urology by Nelson et al.
The objective of this study was to explore the impact of Acceptance and Commitment Therapy (ACT) in men with prostate cancer undergoing treatment for erectile dysfunction (ED) using intracavernosal injection therapy (ICIT). A randomized controlled trial compared ICIT + ACT against ICIT + Enhanced Monitoring and Education (EME). This ongoing study recruited 191 subjects and presented preliminary findings at 6- and 12-month intervals.
Results demonstrated that the ACT group showed significantly increased utilization of injections per week and higher compliance with ICIT compared to the EME group at 6 and 12 months. Additionally, the ACT group reported enhanced satisfaction with ED treatment and overall sexual relationships, along with reduced sexual bother, prostate cancer treatment regret, negative psychological impact from cancer, and depressive symptoms. These preliminary findings suggest that ACT intervention positively influences treatment adherence, satisfaction, and various psychosexual variables in men undergoing ICIT for ED related to prostate cancer.
Source: auajournals.org/doi/10.1097/JU.0000000000003251.01
